Investigating The Utility Of Therapeutic Drug Monitoring Of Beta-lactam Antibiotics In Hospitalised Patients
Funder
National Health and Medical Research Council
Funding Amount
$215,887.00
Summary
The appropriate dosing of antibiotics for patients admitted to hospital is based on broad guidelines derived from studies in healthy volunteers or in patients that may have different types of infections. Minor changes in the clinical state of the patients can require significant dosing adjustments. The best way to guarantee appropriate antibiotic therapy is to individualize doses based on blood concentration data. We aim to determine the utility of dose adjustment in hospitalized patients.
Prof Paterson is an Infectious Diseases Physician studying the molecular and clinical epidemiology of infections with Gram negative bacteria producing newer beta-lactamases.
The Use Of Dosing Software With Bayesian Forecasting To Improve Antimicrobial-plasma Concentrations In The Intensive Care Unit
Funder
National Health and Medical Research Council
Funding Amount
$77,422.00
Summary
Emerging technologies such as DSBF is capable of assisting clinicians with selecting dosing regimens that achieve the target antimicrobial concentrations needed for treating infections. We will conduct a clinical trial to investigate the ability of DSBF to improve antimicrobial concentrations of patients in the ICU. The results of this study may lead to clinicians being given a new powerful validated tool for improving the treatment outcomes of patients suffering from infections in the ICU.
Nanoengineering materials to combat antimicrobial resistance. This project aims to understand how nanoengineered materials can be designed to kill bacteria and fungi without causing antimicrobial resistance. Resistance to antimicrobial drugs already leads to many thousands of deaths annually and costs society billions of dollars. Nanomaterials have unique abilities to attack microbes in multiple ways that could limit resistance. This project will engineer new antimicrobial nanomaterials tailored ....Nanoengineering materials to combat antimicrobial resistance. This project aims to understand how nanoengineered materials can be designed to kill bacteria and fungi without causing antimicrobial resistance. Resistance to antimicrobial drugs already leads to many thousands of deaths annually and costs society billions of dollars. Nanomaterials have unique abilities to attack microbes in multiple ways that could limit resistance. This project will engineer new antimicrobial nanomaterials tailored to selectively kill microbes with reduced likelihood of developing resistance by using synergies between inorganic nanoparticles and antimicrobial peptides. This technology could be used to prevent infections and biofilms on surfaces in a wide range of future applications, such as medical / veterinary devicesRead moreRead less
There is huge interest in the development of bioactive peptides and proteins for the treatment of a wide range of diseases. However, the biggest challenge in the development of peptide and protein drugs is overcoming their poor stability in the human body. The aim of my research is to develop novel methods that provide therapeutically promising peptides and proteins the ability to resist the body’s natural degradation pathways so they can reach their biological target and act as effective drugs.
Male Chlamydia Infections: The Key Role Of Macrophages In Testicular Dissemination And Disrupted Spermatogenesis
Funder
National Health and Medical Research Council
Funding Amount
$868,464.00
Summary
Male partners of couples seeking IVF, who are seropositive for Chlamydia, indicating a prior infection, often have significantly impaired sperm quality (reduced motility, increased DNA damage and abnormal sperm morphology). Our studies will define how Chlamydia are transported to the testis from the penis and how chronic chlamydial infection in the testis disrupts sperm development. We will also develop new antibiotic delivery systems to improve treatment of male chlamydial infections.
Once treatable infections are becoming deadly because bacteria are developing broad antibiotic resistance. New medicines are urgently needed. Microbes themselves are the richest known source of new antibiotics but finding the 'good bugs' is like finding a needle in a microbial haystack. This project will use state-of-the art science to screen a previously overlooked source of rich microbial biodiversity and find new antibiotics.